Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Japan Exports to U.S. Rebound in November as Tariff Impact Eases, Boosting BOJ Rate Hike Expectations 
How to support someone who is grieving: five research-backed strategies 
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Columbia Student Mahmoud Khalil Fights Arrest as Deportation Case Moves to New Jersey 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Chinese Robotaxi Stocks Rally as Tesla Boosts Autonomous Driving Optimism 
Bank of Japan Poised for Historic Rate Hike as Inflation Pressures Persist 
Yes, government influences wages – but not just in the way you might think 
6 simple questions to tell if a ‘finfluencer’ is more flash than cash 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Gold and Silver Prices Dip as Markets Await Key U.S. Economic Data 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
U.S. Dollar Slips Near Two-Month Low as Markets Await Key Jobs Data and Central Bank Decisions 
7-Eleven will begin test-driving 'Neubie', an autonomous, short-range delivery robot equipped with a camera-based autonomous driving system at a store in Seoul's Seocho district.
According to the convenience store chain, Neubie demonstrates outstanding maneuverability in urban areas and could deliver under various weather conditions.
7-Eleven will focus on the robot's systematic and operational improvement as it adjusts to the open, complex urban environment rather than limited indoor spaces like buildings and shops.
The convenience store chain will expand the robot's service area to 300 meters and introduce an additional number of robots in the next three months of the intensive trial period.
